Association of Testosterone-Induced Neutrophil and Monocyte Elevation with Thromboembolic Risk: Insights from the TRAVERSE Trial
The TRAVERSE trial reveals that testosterone replacement therapy elevates neutrophil and monocyte counts in hypogonadal men, correlating with increased venous thromboembolism and cardiovascular event risk, underscoring the need to monitor these leukocytes during therapy.